US Neurology Editorial Board member, Aksel Siva (Istanbul University, Cerrahpaşa School of Medicine, Istanbul, Turkey), discusses latest initiatives in the diagnosis of neuro-Behçet disease, a rare and relatively unknown neurological disorder, as well as promising investigational therapies.
- How can MRI imaging parameters be used in the differential diagnosis of neuro-Behçet disease and other central nervous system inflammatory disorders? (0:04)
- What are the limitations of current treatment options for neuro-Behçet disease? (3:17)
- What investigational therapies appear most promising? (5:39)
View Part 1 of this expert interview here.
Speaker disclosures: Aksel Siva has nothing to disclose in relation to this video interview.
Filmed at the American Academy of Neurology (AAN) Annual Meeting, Philadelphia, USA, May 2019.
Share this Video
Related Videos In Rare Diseases
Lisa Sarfaty: Help support Rare Disease Day
Our society partner, NORD (The National Organization for Rare Disorder) has planned several initiatives to support this year’s Rare Disease Day on 28 February. These activities are aimed at raising awareness about rare diseases and the challenges faced by people living with these conditions. In this video, Lisa Sarfaty, NORD’s VP of Communication and Engagement, […]
Lisa Sarfaty: Exploring and addressing inequities in rare diseases
Rare diseases can present numerous challenges for those living with these conditions and the healthcare professionals caring for them. In this interview we discuss some of these with Lisa Sarfaty, VP of Communication and Engagement for NORD (The National Organization for Rare Disorders) and explore ways in which they could be tackled. Questions Could you […]
Francesco Saccà, EAN 2022: Improving quality of life for patients with generalized myasthenia gravis – ADAPT trial findings
The ADAPT trial (NCT03669588) supported US Food and Drug Administration approval of efgartigimod alfa-fcab in generalized myasthenia gravis. Dr Francesco Saccà (University of Naples Federico II, Naples, Italy) discussed the findings of the study, in terms of health-related quality-of-life outcomes. Questions: 1. What are the current challenges in managing cases of generalized myasthenia gravis? (00:14) […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!